AbbVie Inc. $ABBV Shares Sold by Simplify Asset Management Inc.

Simplify Asset Management Inc. lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 35.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,777 shares of the company’s stock after selling 13,106 shares during the quarter. Simplify Asset Management Inc.’s holdings in AbbVie were worth $5,433,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of ABBV. Wealthquest Corp acquired a new stake in shares of AbbVie during the 4th quarter worth approximately $778,000. Lathrop Investment Management Co. grew its stake in shares of AbbVie by 1.6% during the 4th quarter. Lathrop Investment Management Co. now owns 4,355 shares of the company’s stock worth $995,000 after purchasing an additional 67 shares during the period. Summit Asset Management LLC grew its stake in shares of AbbVie by 1.0% during the 4th quarter. Summit Asset Management LLC now owns 4,909 shares of the company’s stock worth $1,122,000 after purchasing an additional 51 shares during the period. Darden Wealth Group Inc grew its stake in shares of AbbVie by 3.2% during the 4th quarter. Darden Wealth Group Inc now owns 4,775 shares of the company’s stock worth $1,091,000 after purchasing an additional 148 shares during the period. Finally, Clune & Associates LTD. grew its stake in shares of AbbVie by 2.3% during the 4th quarter. Clune & Associates LTD. now owns 18,436 shares of the company’s stock worth $4,212,000 after purchasing an additional 419 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a positive opinion from the European Medicines Agency’s CHMP for MAVIRET in acute hepatitis C, a potential label expansion that could broaden the drug’s commercial opportunity in Europe. Article Title
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, also secured a positive CHMP opinion for Boey, adding another potential European growth catalyst for AbbVie’s aesthetics business. Article Title
• Positive Sentiment: AbbVie highlighted new oncology data at ASCO 2026, signaling continued momentum across its next-generation cancer pipeline and supporting longer-term growth expectations. Article Title
• Positive Sentiment: Analyst and media commentary remained constructive, with pieces calling AbbVie a strong dividend pick and a long-term buy, which can reinforce investor confidence in the stock. Article Title
• Neutral Sentiment: AbbVie plans 85 summer layoffs in California tied to its Allergan Aesthetics unit, a cost-cutting move that may draw attention but is not large enough on its own to materially change the investment case. Article Title

AbbVie Stock Performance

AbbVie stock opened at $216.02 on Monday. The company’s fifty day moving average price is $208.72 and its 200 day moving average price is $219.73. AbbVie Inc. has a 1 year low of $181.71 and a 1 year high of $244.81. The stock has a market capitalization of $381.65 billion, a P/E ratio of 106.41, a P/E/G ratio of 0.74 and a beta of 0.32.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter last year, the company earned $2.46 EPS. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. Sell-side analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Barclays assumed coverage on shares of AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Evercore set a $235.00 price objective on shares of AbbVie in a research note on Friday, May 15th. Finally, Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 17th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.43.

Insiders Place Their Bets

In related news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by company insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.